NYSE$ATIP

ATI Physical Therapy Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Experienced growth in visits, rate per visit, revenue, and adjusted EBITDA.

ATI Physical Therapy reported a revenue increase of 9.2% to $188.1 million, driven by a 6.4% increase in visits per day and a 3.4% increase in rate per visit. The company's net loss decreased to $2.6 million, and Adjusted EBITDA increased by 77.5% to $16.6 million.

  • Net revenue increased by 9.2% compared to the second quarter of 2023.
  • Visits per Day (VPD) increased by 6.4% compared to the second quarter of 2023.
  • Rate per Visit (RPV) increased by 3.4% compared to the second quarter of 2023.
  • Adjusted EBITDA increased by 77.5% compared to the second quarter of 2023.

Headline financials

Total Revenue

$188M

Previous: $172M+9.2%
EPS (adj)

-$2.39

Previous: -$17.97+86.7%
Visits per Day

24.9K

Previous: 23.4K+6.4%
VPD per Clinic

28.4

No prior period
Rate per Visit

$108.32

Previous: $104.74+3.4%
Capital Expenditures

-$3.02M

Previous: $4.56M-166.3%
Net Income

-$2.6M

Previous: -$21.7M+88.0%
Operating Income

$6.89M

Previous: -$12.4M+155.7%
Gross Profit

$30M

Previous: $26.6M+13.1%
Stock-Based Comp

$1.97M

Previous: $2.75M-28.5%

Revenue & EPS history

ATI · Revenue · Quarterly

$188M

Q2 2024+9.2%vs Q2 2023
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

ATI · $177M total across 2 segments · Q3 2023

  • Net Patient Revenue
    $162M+14.0%
  • Other Revenue
    $15.2M+5.0%

Forward guidance

For the third quarter of 2024, ATI expects net revenue to be in the range of $180 million to $190 million, representing approximately 1% to 7% year-over-year growth. The Company anticipates it will continue growing patient visits through 2024 as it executes on its commercial, people, and operations strategies. ATI expects Adjusted EBITDA in the third quarter of 2024 to be in the range of $9 million to $14 million.

Tailwinds

  • Net revenue expected to be in the range of $180 million to $190 million.
  • Net revenue represents approximately 1% to 7% year-over-year growth.
  • Patient visits are expected to continue growing through 2024.
  • Commercial strategies are expected to drive growth.
  • People and operations strategies are expected to drive growth.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-1.1%

Avg return

Earnings day

-4.5%

Avg return

5 days after

-13.0%

Avg return

30 days after

50%

9 / 18 earnings

Positive

+50.0%

Q4 2022

Best reaction

-43.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+4.5%+0.0%-5.6%
Q3 2024-43.8%-53.5%-81.8%
Q2 2024-7.3%-4.9%-8.6%
Q1 2024+1.1%-13.0%-27.9%
Q4 2023+7.9%+2.8%-13.0%
Q3 2023+4.7%-4.5%-9.5%
Q2 2023+2.0%+15.5%+20.1%
Q1 2023-0.3%-2.3%+1.9%
Q4 2022+50.0%+36.0%+8.8%
Q3 2022-37.2%-37.4%-73.4%
Q2 2022-7.1%-15.2%-5.4%
Q1 2022+2.7%-2.1%-10.6%
Q4 2021-9.2%-8.2%-4.6%
Q4 2019-9.2%-8.2%-4.6%
Q3 2021+27.6%+29.5%+19.2%
Q2 2021-6.3%-6.6%-12.4%
Q1 2021+0.1%
Q4 2020-0.5%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro